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Tbjectives: Endothelial nitric oxide synthase (type III) generates nitric oxide, which
ilates blood vessels. Recently, it was discovered that arterial smooth muscle cells
xpress neuronal nitric oxide synthase (type I). The purpose of this study was to
etermine the relative amounts of neuronal nitric oxide synthase in the human
nternal thoracic artery and saphenous vein.
ethods: Remainder segments of internal thoracic arteries and saphenous veins
ere obtained from 45 patients during coronary artery bypass grafting. Western
lotting used specific antibodies against the 3 isoforms of human nitric oxide
ynthase and -actin (for normalization) to measure the relative amounts of the 3
soforms of nitric oxide synthase proteins in vessel specimens. Immunohistochem-
stry was used to localize the 3 proteins in specific cells.
esults: Western blotting detected all 3 isoforms of nitric oxide synthase in the
uman internal thoracic artery. The band density (normalized to -actin) of neuronal
itric oxide synthase was not significantly different from the band density of
ndothelial nitric oxide synthase. The amounts of neuronal nitric oxide synthase in
rteries and veins were equal. Immunohistochemistry showed that the highest
xpression of endothelial nitric oxide synthase was in endothelial cells, but some
xpression was also seen in smooth muscle cells. Most of the neuronal nitric oxide
ynthase was in smooth muscle cells. The location and relative amounts of inducible
itric oxide synthase were variable.
onclusions: Neuronal nitric oxide synthase is expressed in the vascular smooth
uscle of patients undergoing bypass, and the amount in the internal thoracic artery
s the same as in the saphenous vein.
n 1980, it was discovered that the endothelium of blood vessels releases a substance
that acts on the underlying smooth muscle, causing it to relax.1 In 1987, thi
vasodilator substance was shown to be nitric oxide (NO). 2 The NO is generate
rom L-arginine by the enzyme nitric oxide synthase (NOS). Three isoforms of NOS
ave been described: neuronal NOS (nNOS; type I), inducible NOS (iNOS; type II), and
ndothelial NOS (eNOS; type III).3,4 It is commonly thought that the major enz
atalyzing the formation of NO in blood vessels is eNOS, which is located in endothelial
ells. Recently, however, an article in the Journal provided evidence that there is about
s much eNOS in the smooth muscle cells as there is in endothelial cells, the human
nternal thoracic artery (ITA), and the radial artery but not in the saphenous vei5
t was suggested that the eNOS expressed in the smooth muscle cells of the ITA is
mportant for helping to prevent atherosclerosis and that it might account for the longer
ife of ITA grafts compared with SV grafts. 5
It has also been reported that nNOS is expressed in the smooth muscle cells of some
at6 and human7 arteries. The authors of the study that included human arteries
ested that the NO produced by NOS in the smooth muscle cells might modulate arterial
unction independently of NO released from endothelial cells.7 We do not know of any
he Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 5 1131
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CSP tudies showing the expression of nNOS in the human ITA or
V. Thus we undertook this study to see whether and where
NOS might be expressed in the ITA or SV and to test the
ypothesis that there is more nNOS in the ITA than in the SV,
hich could provide an additional reason for the longevity of
TA grafts. In the present experiments we used Western blot-
ing to compare the amounts of eNOS, nNOS, and iNOS in the
TA and to compare the amount of nNOS in the ITA with the
mount in the SV. We also localized each of the 3 isoforms of
OS in the ITA and SV by using immunohistochemistry.
ethods
rteries and Veins
his study was approved by the Institutional Review Board of the
ational University Hospital, National Healthcare Group, Singa-
ore, and the Institutional Review Board of the National Univer-
ity of Singapore. Informed patient consent was obtained before
urgical intervention. Remainder segments of ITAs and sometimes
lso SVs were collected during coronary artery bypass grafting.
lood vessels were collected from 45 patients in this study. The
atients were 80% men, the average age was 60 years, 73% had
ype II diabetes, 16% had type I diabetes, and 11% were nondia-
etic. The patients for whom Western blot data are presented were
ll being treated for hypertension: 88% were taking -blockers,
9% were taking angiotensin-converting enzyme inhibitors, and
2% were taking calcium-channel blockers. Eighty-two percent
ad hyperlipidemia, and 59% had a history of smoking.
Immediately after the surgeon cut off the remainder segment of the
TA, the adhering connective tissue was carefully removed from the
urface (requiring 5 minutes). The cleaned remainder segment, usu-
lly about 10 mm long, was usually cut into shorter segments. A
-mm segment was rinsed in phosphate-buffered saline (PBS; 8 g/L
aCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, and 0.24 g/L KH2PO4) and
mmersed in buffered 10% (vol/vol) formalin for subsequent paraffin
mbedding and immunohistochemistry. A 3-mm segment was rinsed
n PBS, immediately snap-frozen in liquid nitrogen, and stored at
80°C before protein extraction for Western blotting. The remaining
egment was immersed in RNAlater reagent (Qiagen) for subsequent
NA extraction and reverse transcription–polymerase chain reaction
RT-PCR). A remainder segment of the SV was collected from some
f the patients. We did not need to clean it because the assisting
Abbreviations and Acronyms
eNOS  endothelial nitric oxide synthase
iNOS  inducible nitric oxide synthase
ITA  internal thoracic artery
nNOS  neuronal nitric oxide synthase
NO  nitric oxide
NOS  nitric oxide synthase
PBS  phosphate-buffered saline
RT-PCR reverse transcription–polymerase chain
reaction
SV  saphenous veinurgeon had already removed the adhering connective tissue. The SV r
132 The Journal of Thoracic and Cardiovascular Surgery ● Novad been gently distended with heparinized blood. Histologic sections
sually showed an intact endothelium.
easurement of NOS mRNA With RT-PCR
otal RNA was extracted with Trizol and reverse transcribed to
DNA. Conventional polymerase chain reaction was carried out on
he cDNA by using primers that were custom made for us by
esearch Biolabs, Singapore. For the nNOS PCR (Figure 1, A), we
sed the following primer pair: forward, GTACCGAGCCCT-
AAGGAGC; reverse, GGTTGTCATCCCTCATCCG. We used
p the arteries from many of the patients in the early phase of this
tudy while attempting to obtain quantitative results with real-time
T-PCR. We tested many NOS primers, some previously used in
ther laboratories, and many we designed with Gene Runner
oftware, but none of them yielded quantitatively reliable real-time
T-PCR results. The reason was that we could not find primers
hat were both isoform specific and did not have problematic
rimer dimer formation because of the high GC content and the
igh degree of identities among the 3 NOS cDNAs.
easurement of NOS Proteins With Western Blotting
otal protein was extracted from the frozen human blood vessels by
ulverizing them with a mortar and pestle under liquid nitrogen,
ogether with modified RIPA buffer containing freshly added protease
nhibitor cocktail (Sigma Aldrich, St. Louis, Mo). Protein extracts
ere stored at80°C in small aliquots to avoid repeated freeze-thaw
ycles, which degrade the NOS proteins. Standard sodium dodecyl-
ulfate–polyacrylamide gel electrophoresis separation of the extracted
roteins with 7.5% polyacrylamide precast gels (Bio-Rad) was carried
ut. Gels were Western blotted onto polyvinylidene difluoride mem-
ranes, and the blots were incubated overnight at 4°C with anti-NOS
r anti--actin antibodies. Specific antibodies against each of the 3
soforms of human NOS were purchased from BD Transduction
abs, BD Biosciences, Singapore Distributor. We visualized the
ands on the Western blots by means of chemiluminescence with
CL Western Blotting Detection Reagents (GE Healthcare, Chalford
t. Giles, UK). Band density was measured with Quantity One (Bio-
ad) software. The NOS band density was normalized to the -actin
and in the same lane by dividing the NOS density by the -actin
ensity.
ocalization of NOS Proteins in Histologic Sections
mmunohistochemistry was used to identify cells expressing each
f the 3 isoforms of NOS protein in paraffin sections of arteries
nd veins. We blocked endogenous peroxidase in the 5-m sec-
ions with 3% vol/vol H2O2 in methanol and retrieved antigen by
eating almost to boiling in pH 6 sodium citrate buffer. Nonspe-
ific sites were blocked with 2.5% bovine serum albumin plus 10%
orse or goat (depending on which secondary antibody was being
sed) serum. The PBS used throughout contained 0.2% vol/vol
ween 20 and, except for the blocking solution above, also con-
ained 2.5% wt/vol bovine serum albumin and 4% vol/vol horse or
oat serum. Sections were incubated overnight at 4°C in PBS
ontaining one of the primary antibodies. In addition to using the
ame antibodies from BD Transduction Labs as were used for
estern blotting, we also used primary antibodies from Santa Cruz
iotechnology. Antibodies from these 2 sources produced similaresults. After incubation with primary antibody, we used proce-
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Pures and reagents from Vectastain ABC Kits to attach a second-
ry antibody (and then peroxidase) to the primary antibody and a
AB kit to produce brown stain from the peroxidase (kits were
rom Vector Laboratories, Burlingame, Calif). The secondary an-
ibody in the ABC kits contained biotinylated secondary antibody
aised in horse against mouse IgG or in goat against rabbit IgG,
epending on which primary antibody was being used. Negative
ontrols, in which primary antibody was omitted from the PBS
sed for the overnight incubation (see above), showed that the
econdary antibody and peroxidase did not bind to anything other
han the primary antibody (Figures 2, D and 3, D). Hematoxylin
nd Scott’s blue were used for background staining.
ata Analysis
estern blot normalized densities were expressed as means 
tandard error. The 3 means for the isoforms of NOS were com-
ared by using repeated-measures analysis of variance with Bon-
erroni adjustments for pairwise 2-tailed comparisons, and the 2
eans for nNOS in ITAs and SVs were compared by using the
aired 2-tailed t test. Exact P values are reported.
esults
T-PCR Studies
n agarose gel of the products of a PCR carried out onDNA from an ITA and an SV by using nNOS primers is F
The Journal of Thoracichown in Figure 1, A. The primers used generate a 161
roduct from nNOS cDNA; it is clear from the bands seen
n the gel at 161 bp that nNOS mRNA is expressed in both
he ITA and the SV. The smaller-sized bands are primer
imer. Comparable results were obtained with primers for
NOS and eNOS, indicating that all 3 NOS mRNA isoforms
re expressed in both ITAs and SVs.
estern Blot Studies
estern blots of the protein extracted from the ITA of a
atient are shown in Figure 1, B. In this patient the density
he iNOS band was less than the density of the eNOS and
NOS bands, whereas in some other patients it was greater.
he densities of the NOS bands on the Western blots were
ormalized to the density of the -actin bands in the same lane.
he bar graph in Figure 1, C, compares the average normaliz
and density of each isoform of NOS in the ITAs from 13
atients, and Table 1 gives the numeric values. From P
alues in Table 1, it can be seen that there is a
robability that the normalized average density for the
NOS band would be greater than the average for the eNOS
and if we were to test the ITAs of hundreds of patients.
Figure 1. Reverse transcription–poly-
merase chain reaction (RT-PCR) and
Western blot results. A, Agarose gel
of RT-PCR products. Primers for neu-
ronal nitric oxide synthase (nNOS),
which produce a 161-bp product,
were used. Lane 1, Negative control;
lanes 2 and 3, nNOS cDNA standard,
8 copies per tube; lane 4, 800 copies;
lanes 5-10, internal thoracic artery
(ITA) cDNA (2 concentrations); lanes
11-16, saphenous vein (SV; 2 concen-
trations). B, Western blot of protein
extracted from an ITA. The 3 NOS an-
tibodies and the -actin antibody all
stained protein bands at the expected
molecular weights (not indicated).
eNOS, endothelial nitric oxide syn-
thase; iNOS, inducible nitric oxide syn-
thase. C, Normalized (to -actin) den-
sities of the bands for the 3 isoforms of
NOS in ITAs from 13 patients. Data are
presented as means  standard error
(eNOS vs nNOS: P  .08; eNOS vs
iNOS: P  .70; and nNOS vs iNOS: P 
.12). D, Normalized densities of nNOS
bands for the ITAs and SVs from 10
patients. Data are presented as means
 standard error (P  0.19).igure 1, D, shows the average normalized amounts of
and Cardiovascular Surgery ● Volume 132, Number 5 1133
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CSPNOS in the ITAs and SVs from 10 patients. The means 
tandard errors were as follows: 0.60  0.11 for ITAs and
.67 0.12 for SVs. The paired t test for comparison of the
verage amount of nNOS in ITAs (relative to -actin)
ersus the corresponding amount in SVs yielded a P value
f .19. This is usually considered nonsignificant, although
here is an 81% probability that the average amount of
NOS in the SV is greater than in the ITA.
mmunohistochemistry Results
here was considerable variation among patients in the
mounts of each NOS isoform found in the ITA samples by
able 1. Normalized density of the Western blot bands for
he 3 isoforms of nitric oxide synthase in the human inter-
al thoracic artery
eNOS nNOS iNOS
ean 0.45 0.53 0.41
E 0.08 0.06 0.07
NOS vs nNOS: P  .08; eNOS vs iNOS: P  .70; nNOS vs iNOS: P  .12
n  13). P values are defined as the probability that the observed
ifference is due to chance selection of the sample. eNOS, Endothelial
itric oxide synthase (NOS III); nNOS, neuronal NOS (NOS I); iNOS,enducible NOS (NOS II); SE, standard error of the mean.
134 The Journal of Thoracic and Cardiovascular Surgery ● Noveans of Western blotting, and similar variations were found
ith immunohistochemistry. Figure 2 shows the expression
ach of the 3 isoforms of NOS in an ITA from a patient with
 relatively low amount of nNOS in smooth muscle (Figure 2,
) and no discernible iNOS (Figure 2, C). Some nNOS stain
ng can also be seen in the endothelial cells. In this patient there
as an appreciable amount of eNOS in the smooth muscle
ells, and eNOS staining was very strong in the endothelium,
s expected (Figure 2, B). Figure 3 shows sections of the 
rom a patient showing a large amount of nNOS in the smooth
uscle cells (Figure 3, A). There was also some nNOS in 
ndothelial cells of this artery. The ITA from the same patient
howed some eNOS in the smooth muscle cells, but a much
tronger staining for eNOS was seen in the endothelium 
re 3, B). Staining for iNOS was seen in the ITA from
atient in both smooth muscle (media) and endothelium 
re 3, C). The SV of this same patient shows abundant sta
or nNOS in the smooth muscle cells (Figure 3, E), and ther
as also a little eNOS in the media (Figure 3, F).
iscussion
oth iNOS and eNOS proteins have been measured with
estern blotting in human ITAs.8 To our knowledge, how-
Figure 2. Nitric oxide synthase (NOS)
immunohistochemistry of transverse
sections of the internal thoracic artery
(ITA) from one patient. The ABC perox-
idase method was used to stain brown
the sites where the primary antibody
binds. A, Primary antibody specific for
neuronal NOS (nNOS). B, Primary anti-
body specific for endothelial NOS
(eNOS). C, Primary antibody specific
for inducible NOS (iNOS). D, Negative
control.ver, nNOS protein has not previously been measured in
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PTAs. Neuronal NOS has been detected, by means of im-
unofluorescence, in the human external thoracic artery
nd some other muscular human arteries, where it was seen
n both smooth muscle cells and endothelial cells.7 Similar
o the present studies, these same investigators also ob-
erved a weak expression of eNOS in smooth muscle cells
f the external thoracic artery.7 An immunohistochemistry
tudy of samples of normal and atherosclerotic human aorta
ound that nNOS was expressed in the atherosclerotic ves-
els but not in normal vessels.9 The nNOS in the ather-
clerotic aorta was associated with endothelial and mesen-
hymal cells in the intima.9 A recent review discusse
tudies that suggest that nNOS is inducible and that nNOS
lays a protective role in atherosclerosis.10 In the human SV
NOS has been seen, with immunohistochemistry, in the
edia, as well as in adventitial perivascular nerves.11 i
The Journal of ThoracicSmooth muscle cells of the common carotid artery of the
at express nNOS protein, and Western blots show that
rteries from hypertensive rats (SHR) contain more nNOS
han do arteries from normal rats (WKY).6 Our Western blo
ata, which indicate that there might be as much nNOS
rotein as there is eNOS protein in the ITAs of hypertensive
atients, suggest the possibility that under some conditions
NOS might be able to produce as much NO as eNOS. Both
NOS and nNOS are Ca2-activated enzymes. In endothelial
ells acetylcholine or bradykinin can trigger an increase in
ntracellular Ca2 levels, which then activates eNOS; the re-
ulting NO diffuses to and relaxes the smooth muscle cells. In
ascular smooth muscle cells norepinephrine can trigger an
ncreased intracellular Ca2 concentration, which then con-
racts the cells, but if nNOS is present in the cells, the
Figure 3. Another patient in whom
staining for neuronal nitric oxide syn-
thase (nNOS) was more prominent. A,
Internal thoracic artery (ITA) stained
for nNOS. B, ITA stained for endothe-
lial NOS (eNOS). C, ITA stained for
inducible NOS (iNOS). D, ITA negative
control. E, saphenous vein (SV) stained
for nNOS. F, SV stained for eNOS.ncreased Ca2 concentration might also result in the gen-
and Cardiovascular Surgery ● Volume 132, Number 5 1135
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CSPration of NO, which could moderate the contraction caused
y the norepinephrine. Thus the increased nNOS levels
ound in the arteries of hypertensive rats might be an adap-
ive response to counter the increased blood pressure. More
xperiments are necessary to see whether this might also be
rue in human subjects.
Coronary artery bypass grafts using the SV do not remain
atent for as long as grafts using the ITA. For example, in a
tudy of 2127 coronary artery bypass grafts, only 32% of the
V grafts were still patent 15 years after the operation, whereas
6% of the grafts using the left ITA were still patent after 15
ears.12 Remainder segments of human ITAs have a hi
asal level of NO production than segments of SVs, and
urthermore, the duration of NO release after stimulation with
radykinin is longer with ITAs than with SVs.13 Also, in
esponse to vascular endothelial growth factor, the ITA re-
eases more NO than does the SV.14 The decreased release o
O in the SV might be due to the low or absent expression of
NOS in the smooth muscle cells of the human SV in contrast
o a prominent expression of eNOS in the smooth muscle cells
f the ITA.5 We observed some immunostaining of eNOS
he smooth muscle of both the ITA and the SV, but it was less
ntense than the nNOS staining. Also, it has been reported that
here is less eNOS protein in the endothelial cells of the SV
han in the ITA.15 The authors of all of the latter stu
uggested that a lower NOS activity in SVs than in ITAs might
xplain why SV grafts do not last as long as ITA grafts5,13-15
ith Western blotting, we did not find less nNOS in SVs
ompared with ITAs. Thus our hypothesis that there is more
NOS in the ITA than in the SV was not supported, eliminat-
ng this as a possible explanation of the shorter lifespan of SV
rafts.
Our finding of no major difference in the Western blot
ormalized band density for nNOS compared with eNOS
uggests that there might be as much or more nNOS as there
s eNOS protein in the human ITA. Thus, potentially, in
ome circumstances, nNOS might generate as much NO as
oes eNOS, giving nNOS a significant role in this artery. In
he endothelium-denuded bovine carotid artery, physiolog-
cally active amounts of NO are generated by nNOS in the
mooth muscle cells.16 Further experiments will clarify t
ole of nNOS in the ITA and might provide the basis for
ew treatments of atherosclerosis. Although our results
learly show that a substantial amount of nNOS protein is
resent, we should point out that because a different primary
ntibody must be used for each isoform, the band density
ight not be proportional to the amount of protein. This is
ecause the binding efficiencies of antibodies can vary, and
he amount of secondary antibody that binds to a particular
rimary antibody can also vary. On the other hand, our
omparison of the amount of nNOS in the ITA with the
mount in the SV is on firmer ground because we used the
ame nNOS primary antibody for all of the experiments.
136 The Journal of Thoracic and Cardiovascular Surgery ● NovWe conclude that nNOS is expressed in the smooth
uscle cells of both human ITAs and SVs. Neuronal NOS
ight play a significant role in relaxing the ITA because
here can be as much nNOS in the ITA as there is eNOS.
urther experiments are needed to explore this possibility.
lso, because there is little, if any, difference between the
TA and the SV in the amount of nNOS expressed, differ-
nces in nNOS expression apparently do not contribute to
he difference in the longevity of grafts with these 2 vessels.
We thank Soh-Bee Yeo, Wan-Theng Sing, and Wendy C.-N.
hua for their expert technical assistance.
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